Nikolaos Tsiamis

Dr. Nikolaos Tsiamis

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2013 in Diagnostic Pathology
Verified
Journal Article
Open access
NMNIKOLAOS MACHAIRIOTIS
NIKOLAOS MACHAIRIOTIS
ASAikaterini Stylianaki
Aikaterini Stylianaki
GDGeorgios Dryllis
Georgios Dryllis
Paul ZarogoulidisPaul Zarogoulidis
Paul Zarogoulidis
PKParaskevi Kouroutou
Paraskevi Kouroutou
CMChristodoulos Machairiotis
Christodoulos Machairiotis
Endometriosis is a clinical entity characterized by the presence of normal endometrial mucosa abnormally implanted in locations other than the uterine cavity. Endometriosis can be either endopelvic or extrapelvic depending on the location of endometrial tissue implantation. Despite the rarity of extrapelvic endometriosis, several cases of endometriosis of the gastrointestinal tract, the urinary tract, the upper and lower respiratory system, the diaphragm, the pleura and the pericardium, as well as abdominal scars loci have been reported in the literature. There are several theories about the pathogenesis and the pathophysiology of endometriosis. Depending on the place of endometrial tissue implantation, endometriosis can be expressed with a wide variety of symptoms. The diagnosis of this entity is neither easy nor routine. Many diagnostic methods clinical and laboratory have been used, but none of them is the golden standard. The multipotent localization of endometriosis in combination with the wide range of its clinical expression should raise the clinical suspicion in every woman with periodic symptoms of extrapelvic organs. Finally, the therapeutic approach of this clinical entity is also correlated with the bulk of endometriosis and the locum that it is found. It varies from simple observation, to surgical treatment and treatment with medication as well as a combination of those. Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1968087883113362.

7 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
Kassiani-Maria NastouliKassiani-Maria Nastouli
Kassiani-Maria Nastouli
Anastasios ApostolosAnastasios Apostolos
Anastasios Apostolos
MBMaria Bozika
Maria Bozika
GBGeorgios Boliaris
Georgios Boliaris
PIPanagiotis Iliakis
Panagiotis Iliakis
VPVasileios Panoulas
Vasileios Panoulas
Cardiovascular disease remains the leading cause of mortality among women worldwide, yet coronary syndromes in women continue to be under-recognized and insufficiently represented in clinical research. This review summarizes sex-specific pathophysiological mechanisms, risk factors, clinical presentation, and management considerations in women with coronary syndromes. Women are more likely than men to present with non-obstructive and non-atherosclerotic ischemic phenotypes, including ischemia or angina with non-obstructive coronary arteries, coronary microvascular dysfunction, myocardial infarction with non-obstructive coronary arteries, spontaneous coronary artery dissection, vasospastic angina, and Takotsubo syndrome. These entities often require diagnostic strategies beyond the detection of flow-limiting epicardial stenosis, including cardiac magnetic resonance imaging, intracoronary imaging, and coronary function testing. Traditional cardiovascular risk factors remain important, but several female-specific risk enhancers, including premature menopause, adverse pregnancy outcomes, polycystic ovary syndrome, autoimmune disease, and psychosocial stressors, further modify risk and remain incompletely integrated into routine clinical assessment. Women may also experience diagnostic delays due to symptom misclassification, lower baseline troponin concentrations, and clinical algorithms historically derived from male-predominant populations. Management should follow guideline-directed therapy when appropriate, while recognizing sex-related differences in pharmacology, bleeding risk, revascularization outcomes, and the need for phenotype-specific treatment in INOCA, MINOCA, SCAD, and Takotsubo syndrome. Finally, transgender and gender-diverse individuals remain largely absent from cardiovascular trials, highlighting the need for inclusive research frameworks that distinguish sex, gender identity, and hormone exposure. Improved recognition of sex- and gender-related differences is essential to advance equitable cardiovascular care.

12 January 2026 in Life
Verified
Journal Article
Open access
PDF file
Nikolaos TsiamisNikolaos Tsiamis
Nikolaos Tsiamis
DADimitrios Afendoulis
Dimitrios Afendoulis
CTChristos Tountas
Christos Tountas
Fotios Theodorou ToulgaridisFotios Theodorou Toulgaridis
Fotios Theodorou Toulgaridis
FTFlora Tsakirian
Flora Tsakirian
KTKonstantinos Tsioufis
Konstantinos Tsioufis
Background: Cardiac amyloidosis (CA) is characterized by progressive myocardial infiltration leading to restrictive cardiomyopathy and heart failure. While left ventricular assessment has traditionally dominated prognostic evaluation, right ventricular (RV) dysfunction and RV–pulmonary artery (PA) coupling have emerged as critical determinants of outcomes. Objectives: This review synthesizes current evidence on RV–PA coupling as a prognostic marker in cardiac amyloidosis, examining measurement methodologies, prognostic significance, pathophysiological mechanisms, and clinical applications. Methods: We comprehensively reviewed the recent literature on RV–PA coupling in CA, focusing on studies published from 2020 to 2025, including both AL and ATTR subtypes. We analyzed data from multicenter cohorts, prospective registries, and validation studies examining the relationship between RV–PA coupling indices and clinical outcomes. Results: RV–PA coupling, most commonly assessed using the tricuspid annular plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP) ratio, consistently demonstrates strong independent prognostic value for mortality and heart failure outcomes in CA patients. Impaired coupling (TAPSE/PASP < 0.45 mm/mmHg) identifies high-risk patients with hazard ratios ranging from 1.98 to 4.17 for adverse outcomes. In a multicenter cohort of 283 patients, TAPSE/PASP < 0.45 mm/mmHg was independently associated with death or heart failure hospitalization (HR 1.98, 95% CI 1.32–2.96, p = 0.001) and significantly improved risk reclassification (NRI 0.46–0.49). In ATTR-specific populations receiving disease-modifying therapy, impaired coupling (TAPSE/PASP ≤ 0.382 mm/mmHg) predicted three-year mortality with an adjusted HR of 2.99. The coupling index provides incremental value over individual RV parameters by accounting for afterload conditions and demonstrates consistent prognostic performance across both AL and ATTR subtypes. Conclusions: RV–PA coupling represents a robust, easily obtainable prognostic marker that should be routinely assessed in CA patients for risk stratification and clinical decision-making. The TAPSE/PASP ratio can be calculated from standard echocardiographic examinations without additional cost or time, making it practical for widespread implementation. Future research should focus on standardizing measurement protocols, establishing disease-specific thresholds, evaluating coupling trajectories with novel therapies, and integrating coupling assessment into staging systems and management algorithms. The strong prognostic signal, pathophysiological relevance, and ease of measurement position RV–PA coupling as an essential component of comprehensive cardiac amyloidosis evaluation.

1 July 2026 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
Nikolaos TsiamisNikolaos Tsiamis
Nikolaos Tsiamis
Fotios Theodorou ToulgaridisFotios Theodorou Toulgaridis
Fotios Theodorou Toulgaridis
ESEleni Stefanou
Eleni Stefanou
CTChristos Tountas
Christos Tountas
GTGeorgios Tsitsinakis
Georgios Tsitsinakis
Christo KOLEChristo KOLE
Christo KOLE

24 April 2026 in Life
Verified
Journal Article
Open access
PDF file
Nikolaos TsiamisNikolaos Tsiamis
Nikolaos Tsiamis
DADimitrios Afendoulis
Dimitrios Afendoulis
CTChristos Tountas
Christos Tountas
Christo KOLEChristo KOLE
Christo KOLE
FTFlora Tsakirian
Flora Tsakirian
KTKonstantinos Tsioufis
Konstantinos Tsioufis
Traditional cardiovascular assessment has historically focused on the isolated evaluation of either atrial or ventricular structure and function. However, the left atrioventricular coupling index (LACI) represents a paradigm shift by moving beyond single-chamber metrics to quantify the dynamic interaction between the left atrium and left ventricle. Defined as the ratio of left atrial end-diastolic volume to left ventricular end-diastolic volume, LACI integrates structural and functional aspects of cardiac performance. This comprehensive review examines the physiological basis of how the left atrium and ventricle operate as an integrated hemodynamic unit. We detail current measurement methodologies, including two- and three-dimensional echocardiography, cardiac computed tomography, and cardiac magnetic resonance imaging, which serves as the reference standard. Furthermore, the review explores the pathophysiological mechanisms driving atrioventricular uncoupling, specifically mechanical dysfunction, electromechanical desynchrony, and hemodynamic alterations. Extensive clinical evidence demonstrates LACI’s robust independent prognostic value across diverse cardiovascular conditions, such as heart failure, myocardial infarction, cardiomyopathies, and atrial fibrillation. Observational data suggest that LACI provides a promising prognostic value beyond established risk assessment tools by combining the assessment of both chambers’ interdependence. Finally, we outline future directions for clinical translation, highlighting the necessity for standardized measurement protocols, the integration of artificial intelligence, and the potential of LACI as a target for personalized therapeutic strategies.

3 October 2026 in Tomography
Verified
Journal Article
Open access
PDF file
SKSotirios Kotoulas
Sotirios Kotoulas
ATAndreas S Triantafyllis
Andreas S Triantafyllis
AKAthanasios C. Kotoulas
Athanasios C. Kotoulas
KAKonstantinos Antoniades
Konstantinos Antoniades
IAIbraheem Aqueel
Ibraheem Aqueel
LPLeonidas E Poulimenos
Leonidas E Poulimenos
Background/Objectives: Coronary artery calcification is a leading cause of stent failure and a strong predictor of adverse outcomes after percutaneous coronary intervention (PCI). Accurate characterization of calcium burden, depth, and morphology is central to procedural planning, targeted treatment, and better outcomes. This review summarizes the contemporary armamentarium for imaging calcified coronary lesions, from coronary angiography and computed tomography to advanced intracoronary imaging, and how it facilitates treatment. Methods: We synthesized evidence from landmark studies, validated imaging scoring systems, registries, and current guideline and consensus documents addressing the assessment and imaging-guided treatment of coronary calcification. Results: Invasive angiography shows poor diagnostic accuracy for coronary calcium detection, characterization, and quantification. Coronary CT angiography noninvasively quantifies calcium (Agatston score and three-dimensional volume) and supports preprocedural planning, although it may overestimate calcium volume. Intravascular imaging by means of intravascular ultrasound (IVUS) and optical coherence tomography (OCT) effectively detects coronary calcium. Their use is associated with improved clinical outcomes compared with sole angiographic guidance. The addition of near-infrared spectroscopy (NIRS-IVUS) characterizes lipids within calcified plaque and high-risk calcified nodules. OCT provides the highest spatial resolution and uniquely measures calcium thickness and longitudinal calcium length, while the utilization of artificial intelligence further enhances calcium assessment. Integration of these modalities into a morphology-based, imaging-guided approach facilitates calcium detection and modification and supports PCI optimization. Conclusions: Intravascular imaging, along with coronary CT angiography, has transformed the assessment of calcified coronary lesions. Combining their strengths enables precise, lesion-specific preparation; randomized trials show that intravascular imaging guidance improves outcomes in complex PCI, while CT-guided PCI planning is emerging as a complementary strategy whose clinical value is now being tested in randomized trials.